ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financi...(s CMV and HCV programs; and -- ...),Health

HCV programs; and

-- the timing and nature of potential business development activities

related to the Company's efforts to expand its current portfolio

through in-licensing or other means of acquiring products in clinical

development or marketed products.

These factors, and other factors, including, but not limited to those described in ViroPharma's 2006 annual report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

VIROPHARMA INCORPORATED

Selected Financial Information

(unaudited)

Statements of Operations: Three months ended Nine months ended

(in thousands, except per share

data) September 30, September 30,

-------------------------------------

2007 2006 2007 2006

-------- ------- -------- --------

Revenue:

Net product sales $50,944 $55,105 $156,074 $128,163

Milestone, license fee and other

revenue - 141 - 423

-------- ------- -------- --------

Revenue 50,944 55,246 156,074 128,586

-------- ------- -------- --------

Costs and Expenses:

Cost of sales 2,029 4,868 6,900 1
'/>"/>